Abstracts tagged "Reproductive Health and systemic lupus erythematosus (SLE)"

Abstract Number: 2653 • 2018 ACR/ARHP Annual Meeting
Contraceptive Documentation in Systemic Lupus Erythematosus Patients at a Safety Net Hospital
Ola Azzouqah¹ and Bonnie L. Bermas², ¹Department of Rheumatic diseases, UT Southwestern Medical Center and Parkland Hospital, Dallas, TX, ²Division of Rheumatic Diseases, UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Systemic Lupus Erythematosus (SLE) predominately affects reproductive aged women. Contraceptive counseling is an important quality indicator in SLE patient care. Here we evaluate current…
Abstract Number: 1305 • 2017 ACR/ARHP Annual Meeting
Use of Estrogen-Containing Contraceptives Among SLE Women with and without Contraindications to Estrogen
Arielle Mendel¹, Sasha Bernatsky², Yvan St.Pierre³, Christian Pineau⁴ and Evelyne Vinet⁵, ¹Rheumatology, McGill University, Montreal, QC, Canada, ²Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³McGill University Health Centre, Montreal, QC, Canada, ⁴Rheumatology, McGill University Health Center, Montreal, QC, Canada, ⁵Divisions of Rheymatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Estrogen-containing contraceptives may be contraindicated in specific medical conditions due to an increased risk of cardiovascular and thromboembolic events. Women with SLE are at…
Abstract Number: 2436 • 2016 ACR/ARHP Annual Meeting
Birth Outcomes Significantly Worsen after the Development of Systemic Lupus Erythematosus in a Population-Based Registry
Mary Abraham¹, Lexi Rene¹, Cristina Drenkard² and S. Sam Lim³, ¹Department of Medicine, Emory University, Atlanta, GA, ²Emory University School of Medicine, Atlanta, GA, ³Medicine, Emory University School of Medicine, Atlanta, GA
Background/Purpose: SLE mothers are known to have higher rates of pre-term birth and low birth weight compared to women in the general population. We evaluated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].